Today: 22 November 2025
Subscribe
Browse Category

Pharmaceuticals News 22 July 2025 - 29 August 2025

COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

Drug Approvals & Clinical Trial Results Updated COVID Boosters Get Narrow Nod: The U.S. FDA approved new fall COVID-19 booster shots from Pfizer/BioNTech and Moderna on August 27 – but with strict eligibility limits. Only adults 65+ and younger people with certain medical conditions are cleared for the updated vaccines, and emergency use authorizations for routine use in healthy children were removed realeconomy.rsmus.com. Health experts immediately sounded alarms: the Infectious Diseases Society of America blasted the “narrowed” booster rollout as contrary to scientific guidance and a risk to lives cidrap.umn.edu. They warn these restrictions could hinder access, especially for children,
29 August 2025
 ·  ·  ·  ·  ·  ·  ·  ·  · 
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Regulatory Approvals & Clinical Milestones Pharma & Biotech Industry Moves Startups & Innovation Highlights Medical Research & Innovation Public Health & Policy Developments Sources: Ionis HAE drug approval pharmexec.com biopharmadive.com; BioPharmaDive on Dawnzera pricing and positioning biopharmadive.com biopharmadive.com; AbbVie Rinvoq AA trial via FiercePharma fiercepharma.com; Lancet Neurology SAPPHIRE trial results neurologylive.com neurologylive.com; Reuters – Kite/Gilead’s Interius acquisition reuters.com and Interius press release interiusbio.com; PharmExec on XOMA-Mural deal ts2.tech; Reuters – J&J $2B NC facility and quote ts2.tech ts2.tech; Reuters – Apollo Hospitals stake sale ts2.tech; BiopharmaTrend on Kyorin adopting Elix AI platform biopharmatrend.com biopharmatrend.com; Laotian Times – Amgen Golden Ticket
23 August 2025
 ·  ·  ·  ·  ·  ·  ·  ·  · 
Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Pharmaceutical Industry News (Approvals, Trials & Deals) Biotech Startups & Funding Highlights Medical Research Breakthroughs & Publications Healthcare Policy & Public Health Developments Regulatory Updates from Agencies (FDA, EMA, etc.) Sources: Scientific press releases, company announcements, major news outlets (Reuters, AP, HealthDay, FierceBiotech, etc.), and health agency briefs were used to compile this report reuters.com reuters.com ts2.tech interiusbio.com. Each item includes a citation link to the original source for further reading. This concludes the comprehensive roundup of biotech, pharma, medical, and health news from August 21–22, 2025.
22 August 2025
 ·  ·  ·  ·  ·  ·  ·  ·  · 
Biotech Breakthroughs & Pharma Shakeups – Global Health Roundup (Aug 20–21, 2025)

Biotech Breakthroughs & Pharma Shakeups – Global Health Roundup (Aug 20–21, 2025)

Industry & Corporate Developments Mergers, Acquisitions & Partnerships Regulatory & Drug Approval Updates Public Health & Policy Research & Clinical Breakthroughs Sources: Reuters, Politico, HealthLeaders, BioPharma Dive, FierceBiotech, Pharmaceutical Executive, Technology Networks, McGill University reuters.com reuters.com healthleadersmedia.com reuters.com fiercebiotech.com reuters.com reuters.com technologynetworks.com technologynetworks.com.
21 August 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Major Corporate & Industry Announcements Clinical Trials & Drug Regulatory Updates Scientific & Medical Research Breakthroughs (Note: The above research highlights were reported in peer-reviewed journals and scientific news outlets around this time, underlining the broader scientific context during the news cycle.) Public Health & Policy Highlights Sources: Key information in this report is drawn from reputable industry and news outlets including Reuters reuters.com reuters.com, Fierce Biotech/Pharma fiercebiotech.com fiercebiotech.com, Endpoints News, STAT, and official statements from organizations like the FDA, EMA, WHO, and leading medical journals. For full details and additional context, please refer to the cited sources inline.
20 August 2025
 ·  ·  ·  ·  · 
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Sector – Big Deals, Funding, and FDA Drama Pharma & Drug Development – Approvals, Showdowns, and Safety Signals Medical & Clinical Updates – Guidelines and Safety Notices Public Health & Policy – Vaccine Rift, Medicare Cuts, and Wellness Initiatives Sources: Key news and expert quotes were gathered from Fierce Biotech fiercebiotech.com fiercebiotech.com, Fierce Pharma fiercepharma.com fiercepharma.com, Fierce Healthcare fiercehealthcare.com fiercehealthcare.com, STAT News statnews.com statnews.com, the Florida Phoenix floridaphoenix.com floridaphoenix.com, CIDRAP cidrap.umn.edu cidrap.umn.edu, and other authoritative sources as cited above. Each development is linked to its original reporting for further reading. The roundup covers events and announcements from August 18–19,
19 August 2025
 ·  ·  ·  ·  ·  · 
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy (semaglutide) received FDA accelerated approval to treat metabolic dysfunction-associated steatohepatitis (MASH), becoming the first GLP-1 therapy cleared for MASH in a patient population estimated at about 5% of U.S. adults, based on part 1 of an ongoing trial showing liver health improvement. Tonix Pharmaceuticals’ Tonmya, or TNX-102 SL, was approved August 15 for fibromyalgia, the first new fibromyalgia therapy in 15 years, with two Phase 3 trials showing significantly reduced daily pain versus placebo at 14 weeks and a potential peak U.S. sales of about $800 million. Pfizer’s inclacumab, a P-selectin inhibitor acquired via the 2022 $5.4 billion Global
16 August 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

Researchers in China unveiled a hydrogel-based “smart” wound dressing that speeds diabetic ulcer healing, with a single application achieving about 90% wound closure in 12 days by delivering microRNA-loaded vesicles that suppress the vessel-growth inhibitor TSP-1. A Swedish study published August 8 identified 87 DNA methylation sites in blood from 752 newly diagnosed diabetics followed for seven years, creating a score that predicted cardiovascular outcomes with 96% accuracy for identifying low-risk patients. A natural compound in maple tree syrup, epicatechin gallate (ECG), blocked Streptococcus mutans biofilm formation in lab tests, suggesting potential as a safe plaque-preventing agent in mouthwash or
10 August 2025
 ·  ·  ·  · 
Revolutionary Medical Breakthroughs of July 2025: Life-Changing Drugs, Diagnostic Wonders & Public Health Milestones

Revolutionary Medical Breakthroughs of July 2025: Life-Changing Drugs, Diagnostic Wonders & Public Health Milestones

On July 2, 2025, the FDA granted accelerated approval to linvoseltamab (Lynozyfic), a BCMA-targeting bispecific antibody, for adults with heavily pretreated relapsed/refractory multiple myeloma, after trials showed a 70% response rate. Also on July 2, 2025, the FDA approved sunvozertinib (Zegfrovy) as the first targeted oral therapy for advanced NSCLC with EGFR exon 20 insertion mutations following chemotherapy. In July 2025, the FDA granted Breakthrough Therapy designation to trastuzumab deruxtecan (T-DXd) plus pertuzumab for HER2-positive metastatic breast cancer. Relutrigine (PRAX-562) received FDA Breakthrough Therapy designation for two rare pediatric epileptic encephalopathies (SCN2A and SCN8A) after a Phase 2 study showed
22 July 2025
 ·  ·  ·  · 
1 … 8 9 10
Go toTop